With the Trump administration pushing back against a swath of DEI-related federal grants, some research related to major diseases, including Alzheimer’s, is being caught in the crossfire. The most recent round of grant axing resulted in two major universities losing millions in funding related to studying brain disease, and experts say it could put them at a large disadvantage.
What research is being impacted?
In 2025, the U.S. awarded 52% fewer grants related to Alzheimer’s research than in 2024, according to the National Institutes of Health (NIH), with the number of grants falling from 369 to 177. That figure appears to be on track through 2026 as well, especially given the most recent cuts.
The newest funding slashes involve grant cancellations for “brain health and Alzheimer’s disease research at two leading research institutions, Emory University and the University of Pittsburgh,” said The Guardian. At least “three grants were canceled between the two institutions,” representing $15 million in funds that would’ve been used to study “how discrimination” — or racism — “affects long-term brain health.”
The topics “we’re measuring are scientifically valid concepts,” Andrea Rosso, an associate professor of epidemiology at the University of Pittsburgh, told The Guardian. Black people are two times more likely to develop dementia, according to the Alzheimer’s Association. And while these studies “don’t actually measure structural racism,” they do “use that as a framing for why one population is at such high risk,” said Rosso.
The DEI-related funding cuts are also coming alongside additional efforts by the White House to overhaul how grants are awarded. Under newly proposed rules by the Trump administration, any “multiyear grant could be terminated at any point,” and the government “would not be allowed to fund any DEI-related activities or projects or groups that ‘deny the biological reality of sex or the sex binary in humans,’” said The Boston Globe.
What does this mean for Alzheimer’s patients?
Many are worried that cutting Alzheimer’s research under the guise of the anti-DEI movement could negatively impact patients, specifically those who are Black. One canceled grant at the University of Pittsburgh “studied how Alzheimer’s disease risk was affected in people who live in divested, predominantly African American neighborhoods,” said The Guardian. The research tracked “socially driven Alzheimer’s disease risk factors by collecting surveys, brain imaging and blood samples.” Another grant at Emory University that was slashed by the White House “studied the impact of racial discrimination on the white matter of the brain, in part surveying participants’ self-reported incidences of discrimination.”
Behind all of these killed studies are “people waiting for answers, for therapies, for relief, for hope,” said a pain researcher at Mass General Brigham, per the Globe. This comes as the Trump administration has “been open about wanting a smaller NIH,” said Vox, and originally “proposed cutting the agency’s budget for 2026 by 40%.”
Some researchers say they are considering taking their studies offshore if things do not change. “While I hope to improve the lives of the American people with my research, if I am not able to pursue this aspiration in the U.S., I would rather continue to do so outside of the country,” one Ph.D. student said in comments about the cuts, per the Globe.
The current state of affairs “demonstrates a lack of understanding of our outcomes versus our exposures,” Ann Cohen, an associate professor of psychiatry at the University of Pittsburgh, said to The Guardian. “That’s epidemiology 101.”
At least two major research institutions have been hit with cuts
